Triacetylphosphat | 56858-93-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Triacetylphosphat
• 英文别名: acetic acid phosphoric acid-anhydride；Essigsaeure-phosphorsaeure-anhydrid；acetyl phosphate；Diacetyl acetyl phosphate；diacetyloxyphosphoryl acetate
• CAS: 56858-93-6
• 化学式: C₆H₉O₇P
• 分子量: 224.107
• InChiKey: JBIJMTLVUKEXJO-UHFFFAOYSA-N

物化性质

• 沸点：
  276.7±23.0 °C(Predicted)
• 密度：
  1.381±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  96
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Triacetylphosphat 、 水 生成 (乙酰氧基-羟基磷酰)乙酸酯
  参考文献：
  名称：

  Lynen, Chemische Berichte, 1940, vol. 73, p. 367,368, 373

  摘要：

  DOI：
• 作为产物：
  描述：

  乙酰氯 在 silver orthophosphate 、 乙醚 作用下， 生成 Triacetylphosphat
  参考文献：
  名称：

  Lynen, Chemische Berichte, 1940, vol. 73, p. 367,368, 373

  摘要：

  DOI：
• 作为试剂：
  描述：

  2ˊ-脱氧鸟苷-5ˊ-一磷酸 、 二磷酸腺苷 在 Triacetylphosphat 作用下， 生成 2'-脱氧鸟苷 5'-(四氢三磷酸酯)
  参考文献：
  名称：

  Lehman et al., Journal of Biological Chemistry, 1958, vol. 233, p. 163,165

  摘要：

  DOI：

文献信息

• [EN] METHODS FOR PRODUCING 3-HYDROXY-3-METHYLBUTYRIC ACID<br/>[FR] PROCÉDÉS POUR PRODUIRE DE L'ACIDE 3-HYDROXY-3-MÉTHYLBUTYRIQUE
  申请人：GLOBAL BIOENERGIES

  公开号：WO2016042012A1

  公开（公告）日：2016-03-24

  Described is a method for the conversion of 3-methylcrotonyl-CoA into 3-hydroxy-3- methylbutyric acid comprising the steps of: (a) enzymatically converting 3-methylcrotonyl-CoA into 3-hydroxy-3-methylbutyryl-CoA; and (b) further enzymatically converting the thus produced 3-hydroxy-3-methylbutyryl-CoA into 3-hydroxy-3-methylbutyric acid wherein the enzymatic conversion of 3-hydroxy-3-methylbutyryl-CoA into 3-hydroxy-3-methylbutyric acid according to step (b) is achieved by first converting 3-hydroxy-3-methylbutyryl-CoA into 3-hydroxy-3-methylbutyryl phosphate and then subsequently converting the thus produced 3-hydroxy-3-methylbutyryl phosphate into 3-hydroxy-3-methylbutyric acid.

  描述了一种将3-甲基丙酰辅酶A转化为3-羟基-3-甲基丁酸的方法，包括以下步骤：(a)将3-甲基丙酰辅酶A酶促转化为3-羟基-3-甲基丁酰辅酶A；(b)进一步将所产生的3-羟基-3-甲基丁酰辅酶A酶促转化为3-羟基-3-甲基丁酸，其中根据步骤(b)将3-羟基-3-甲基丁酰辅酶A酶促转化为3-羟基-3-甲基丁酸的方法是首先将3-羟基-3-甲基丁酰辅酶A转化为3-羟基-3-甲基丁酰磷酸，然后随后将所产生的3-羟基-3-甲基丁酰磷酸转化为3-羟基-3-甲基丁酸。
• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。
• MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS
  申请人：Genomatica, Inc.

  公开号：US20150148513A1

  公开（公告）日：2015-05-28

  The invention provides non-naturally occurring microbial organisms having a 4-hydroxybutyrate, 1,4-butanediol, or other product pathway and being capable of producing 4-hydroxybutyrate, 1,4-butanediol, or other product, wherein the microbial organism comprises one or more genetic modifications. The invention additionally provides methods of producing 4-hydroxybutyrate, 1,4-butanediol, or other product or related products using the microbial organisms.

  该发明提供了具有4-羟基丁酸、1,4-丁二醇或其他产物途径并能够产生4-羟基丁酸、1,4-丁二醇或其他产物的非自然微生物生物体，其中该微生物生物体包括一个或多个基因修饰。该发明还提供了利用这些微生物生物体生产4-羟基丁酸、1,4-丁二醇或其他产物或相关产品的方法。
• Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
  申请人：Marnett J. Lawrence

  公开号：US20050250839A1

  公开（公告）日：2005-11-10

  The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and γ-secretase. Also provided are methods of using the derivatives to treat pathological disorders.

  目前披露的主题提供了非甾体类抗炎药（NSAIDs）的衍生物，其特点是具有明显降低的环氧合酶抑制活性，但仍保留与其他多肽（如过氧化物酶体增殖物激活受体（PPARs）和γ-分泌酶）相互作用和调节活性的能力。还提供了使用这些衍生物治疗病理性疾病的方法。
• [EN] COMPOSITIONS COMPRISING AN HIV PROTEASE INHIBITOR<br/>[FR] COMPOSITIONS COMPORTANT UN INHIBITEUR DE LA PROTEASE DU VIH
  申请人：PFIZER

  公开号：WO2005056542A1

  公开（公告）日：2005-06-23

  The present invention relates to pharmaceutical compositions comprising amorphous (4R)-N-allyl-3-(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, their methods of preparation, their use in inhibiting the HIV protease enzyme, and their use in the manufacture of a medicament for the treatment HIV-infected mammals, such as humans.

  本发明涉及包含非晶态(4R)-N-烯丙基-3-(2S,3S)-2-羟基-3-[(3-羟基-2-甲基苯甲酰)氨基]-4-苯基丁酰}-5,5-二甲基-1,3-噻唑烷-4-羧酰胺，或其药学上可接受的盐或溶剂的制药组合物，其制备方法，其在抑制HIV蛋白酶酶的用途，以及其在制造用于治疗HIV感染哺乳动物，如人类的药物中的用途。